Grail has announced a collaboration with athenahealth, which aims to integrate the Galleri multi-cancer early detection (MCED) test ordering into the athenaCoordinator Core, which is designed for the transmission of lab orders and care coordination for healthcare facilities.
This combination will be offered via the cloud-based electronic health record (EHR) solution, athenaOne.
Grail noted that through the alliance, more than 160,000 clinicians in the US on the athenahealth network can choose to directly order the test in the EHR, minimising extra ordering steps.
Once the clinician places an order, individuals can pick up the test kit for an appointment to draw blood, with results automatically updated in their chart.
This process is said to aid in decreasing manual entry and administrative load for the clinician鈥檚 practice.
The Galleri test claims to detect DNA fragments shed by the cancer cells into the bloodstream, which act as a cancer鈥檚 fingerprint.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Grail, the test screens for this fingerprint across many fatal cancers through a single blood draw, even before symptoms arise, including those without current recommended screening tests.
It also offers information on the origin of the cancer, aiding in predicting the type of tissue or organ related to the cancer signal.
This prescription-only test is recommended for the adult population with an increased cancer risk, especially those who are aged 50 or above. It is intended to be used in conjunction with recommended cancer screenings.
Grail president Josh Ofman said: 鈥淐ancer remains a public health crisis. There is a clear need to transform the way we screen for cancer while still asymptomatic, when it can be more easily treated.
鈥淚ntegrating with athenaCoordinator Core will help simplify the Galleri test ordering process as part of routine exams and help increase patient access to MCED to screen for some of the deadliest cancers before they become symptomatic.鈥�
In February, Grail expanded access to the Galleri test in the US through a partnership with Quest Diagnostics.
